Trial reportEuropean journal of clinical pharmacology2004
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
Trial report in European journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.Genetics in medicine : official journal of the American College of Medical Genetics · 2007Guideline
- Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study.The pharmacogenomics journal · 2026Article
- Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling.Frontiers in molecular biosciences · 2026Article
- Pharmacogenomics ofPharmaceutics · 2025Article
- Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.European journal of clinical pharmacology · 2025Article
- Phenoconversion andHepatology forum · 2025Review
- Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Beyond the label: current evidence and future directions for the interrelationship between electronic cigarettes and mental health.Frontiers in psychiatry · 2023Review
- Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports.Journal of personalized medicine · 2022Article
- Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia.Biochemical pharmacology · 2022Article
- Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene.Frontiers in psychiatry · 2022Article
- Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition.Pharmaceutics · 2021Review
- Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.Advances in experimental medicine and biology · 2021Article
- Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.The Journal of pharmacology and experimental therapeutics · 2021Article
- Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.International journal of bipolar disorders · 2020Review
- The Herb-Drug Pharmacokinetic Interaction of Fluoxetine and Its Metabolite Norfluoxetine with a Traditional Chinese Medicine in Rats by LC-MS/MS.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.European journal of clinical pharmacology · 2016Article
- The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?International journal of molecular sciences · 2016Review
- Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Current psychiatry reports · 2015Review
- Clinical applications of CYP genotyping in psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism in vitro and in vivo. CYP2C9 has also been shown to influence the metabolism of fluoxetine in vitro; however, this relationship has not been studied in humans. The aim of the present study was to evaluate the influence of CYP2D6 and CYP2C9 genotypes on the plasma concentration of fluoxetine and norfluoxetine in psychiatric patients during steady-state conditions.
methodsWhite European psychiatric patients ( n=64) receiving antidepressant monotherapy with fluoxetine were studied. CYP2D6 and CYP2C9 genotypes were determined by polymerase chain reaction-specific methods. The plasma concentrations of fluoxetine and its metabolite, norfluoxetine, were measured by high-performance liquid chromatography.
resultsThe dose-corrected plasma concentrations of fluoxetine were related ( P<0.01, r=-0.36) to CYP2D6 genotypes (number of active genes). The fluoxetine/norfluoxetine ratio also correlated ( P<0.01, r=-0.39) with the number of active CYP2D6 genes. Among patients with two CYP2D6 active genes, the dose-corrected plasma concentrations of fluoxetine and active moiety (fluoxetine plus norfluoxetine) were significantly ( P<0.05) higher in the CYP2C9*1/*2 and CYP2C9*1/*3 genotype groups than in CYP2C9*1/*1. However, dose-corrected (C/D) plasma concentrations of fluoxetine, active moiety and fluoxetine/norfluoxetine ratios were not highly different in the individuals with two mutated alleles as compared with those heterozygous for *2 or *3.
conclusionThe present results show that CYP2D6 and potentially CYP2C9 genotypes seem to influence fluoxetine plasma concentration during steady-state conditions in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.